These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
202 related items for PubMed ID: 23267169
1. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW. Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169 [Abstract] [Full Text] [Related]
2. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010. Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW. J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151 [Abstract] [Full Text] [Related]
3. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP, Koopman-Keemink Y, Oranje AP, de Waard-van der Spek FB, Gorter SL, Armbrust W, Dolman KM, Wulffraat NM, van Suijlekom-Smit LW. Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101 [Abstract] [Full Text] [Related]
4. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW. Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187 [Abstract] [Full Text] [Related]
9. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents. Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F. Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003 [Abstract] [Full Text] [Related]
10. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM. Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553 [Abstract] [Full Text] [Related]
11. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, Koopman-Keemink Y, Gorter SL, Raat H, van Suijlekom-Smit LW. Rheumatology (Oxford); 2011 Jun; 50(6):1131-6. PubMed ID: 21278067 [Abstract] [Full Text] [Related]
12. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916 [Abstract] [Full Text] [Related]
13. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW. Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940 [Abstract] [Full Text] [Related]
15. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW. JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397 [Abstract] [Full Text] [Related]